Compounds > n(2),n(6)-dimethyl-9-hydroxyellipticinium
Page last updated: 2024-12-07

n(2),n(6)-dimethyl-9-hydroxyellipticinium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(2),N(6)-dimethyl-9-hydroxyellipticinium: RN given refers to parent cpd; structure given in second source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID125770
CHEMBL ID32580
MeSH IDM0150995

Synonyms (9)

Synonym
CHEMBL32580
69467-90-9
6h-pyrido(4,3-b)carbazolium, 9-hydroxy-2,5,6,11-tetramethyl-
n(2),n(6)-dimethyl-9-hydroxyellipticinium
2,6-dimethyl-9-hydroxyellipticine acetate
2,6-dimethyl-9-hydroxyellipticinium
9-hydroxy-2,6-dimethylellipticinium
2,6-dmhe
9-hydroxy-2,5,6,11-tetramethylpyrido(4,3-b)carbazolium chloride
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID117502The effect on oxygen consumed in the presence of MPO-H2O2.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Bioactivation of the antitumor drugs 9-hydroxyellipticine and derivatives by a peroxidase-hydrogen peroxide system.
AID96644Compound was tested for its antitumor activity against murine leukemia L1210 cells in vitro, expressed as ID501981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Bioactivation of the antitumor drugs 9-hydroxyellipticine and derivatives by a peroxidase-hydrogen peroxide system.
AID116286Increase in life span over control (10e5 cells) in mice after intraperitoneal treatment of the compound.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Bioactivation of the antitumor drugs 9-hydroxyellipticine and derivatives by a peroxidase-hydrogen peroxide system.
AID117798The effect on NADH oxidation in the presence of MPO-H2O2.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Bioactivation of the antitumor drugs 9-hydroxyellipticine and derivatives by a peroxidase-hydrogen peroxide system.
AID96665Growth inhibitory activity against L1210 lymphocytic leukemia cells.1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Autoxidation of the antitumor drug 9-hydroxyellipticine and its derivatives.
AID97904Compound was tested for its cytotoxic activity against murine leukemia L1210 cells in mice after intraperitoneal treatment, expressed as LD0 (highest nonlethal dose).1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Bioactivation of the antitumor drugs 9-hydroxyellipticine and derivatives by a peroxidase-hydrogen peroxide system.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's2 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.28 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ellipticine
ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.		2.3620indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene		antineoplastic agent;
plant metabolite
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		1.9710alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
elliptinium
elliptinium: synthetic ellipticine deriv; RN given refers to parent cpd; structure given in first source		2.8840carbazoles
9-methoxyellipticine
9-methoxyellipticine: RN given refers to parent cpd		1.9610
9-hydroxyellipticine
9-hydroxyellipticine: RN given refers to parent cpd. 9-hydroxyellipticine : A organic heterotetracyclic compound that is ellipticine in which the hydrogen at position 9 has been replaced by a hydroxy group.		2.3620organic heterotetracyclic compound;
organonitrogen heterocyclic compound		antineoplastic agent
2-methylellipticinium
2-methylellipticinium: RN given refers to parent cpd		2.3620
ConditionIndicatedRelationship StrengthStudiesTrials
Acquired Immune Deficiency Syndrome
[description not available]		03.3811
Infections, Retroviridae
[description not available]		03.3811
ARC
[description not available]		03.3811
Fibroma, Shope
[description not available]		03.3811
Acquired Immunodeficiency Syndrome
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.		03.3811
AIDS-Related Complex
A prodromal phase of infection with the human immunodeficiency virus (HIV). Laboratory criteria separating AIDS-related complex (ARC) from AIDS include elevated or hyperactive B-cell humoral immune responses, compared to depressed or normal antibody reactivity in AIDS; follicular or mixed hyperplasia in ARC lymph nodes, leading to lymphocyte degeneration and depletion more typical of AIDS; evolving succession of histopathological lesions such as localization of Kaposi's sarcoma, signaling the transition to the full-blown AIDS.		03.3811
Retroviridae Infections
Virus diseases caused by the RETROVIRIDAE.		03.3811